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Plasma mediators in patients with severe
COVID-19 cause lung endothelial
barrier failure
To the Editor:
Approximately 20% of symptomatic patients with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection progress to severe coronavirus disease 2019 (COVID-19) with critical hypoxaemia
fulfilling the criteria of acute respiratory distress syndrome (ARDS). Consistent with the classic features of
ARDS, severe COVID-19 is characterised by ground glass opacities on computed tomography imaging and
diffuse alveolar damage post mortem [1], suggesting permeability-type lung oedema as driver of respiratory
failure. Consistent with this concept, autopsy findings show severe lung endothelial injury in patients who
succumbed to COVID-19 [2].
At present, the extent of endothelial barrier failure and its underlying mechanisms in COVID-19 remain
unclear. While the occasional presence of viral particles in lung endothelial cells has been reported in
autoptic studies [2], endothelial cells are not thought to be infected directly in SARS [3]. Alternatively,
endothelial barrier failure may be caused by barrier-disruptive mediators released from the infected airspace
epithelium and the consecutive immune response. If so, these mediators and their barrier-disruptive effect
should be recoverable from circulating blood plasma. Here, we provide proof-of-principle for this concept
and report a screening platform for endothelial barrier regulation, that can be utilised to 1) identify
pathological mediators and 2) screen for the therapeutic potential of barrier-stabilising compounds in
COVID-19.
Citrate plasma was sampled as part of the prospective observational Pa-COVID-19 cohort study (ethics
approval EA2/066/20) in 14 patients with moderate (hospitalised, no invasive ventilation; WHO severity
score 3–4) and 19 with severe (high flow O2 or intubated and mechanically ventilated; WHO severity score
5–7) COVID-19. Plasma samples were diluted to 10% (v/v) in cell culture medium without FCS and tested
for their ability to disrupt barrier integrity of primary human pulmonary microvascular endothelial cells
(HPMEC, passage 4–7) monolayers by 1) electrical cell-substrate impedance sensing (ECIS Z-Theta,
Applied BioPhysics), 2) measurement of trans-endothelial electrical resistance (TEER) using a REMS Auto
Sampler (World Precision Instruments), and 3) immunofluorescence for endothelial VE-cadherin and
F-actin. Plasma from 15 healthy donors (ethics approval EA2/075/15) served as control. Samples were
probed for SARS-CoV-2 RNA by real-time RT-PCR. Human lung tissue from non-COVID-19 patients
(ethics approval EA2/079/13) was probed for protein levels of VE-cadherin and occludin following
stimulation with plasma for 24 h. Data are presented as mean±SEM. Different treatment groups were
compared by Mann–Whitney U-test or two-way ANOVA followed by Tukey’s post hoc test. Statistical
significance was assumed at p<0.05.
In contrast to healthy donor plasma, plasma from COVID-19 patients induced a rapid (within 1–2 h) and
sustained (>6 h) increase in endothelial permeability of HPMEC monolayers (figure 1a and b). As shown
by two methods, ECIS and TEER, the decrease in monolayer resistance after 6 h was more pronounced in
plasma from patients with severe as compared to moderate disease. The barrier-disruptive effect of 10%
severe COVID-19 plasma was comparable to that of 50 µmol·L−1 platelet-activating factor, an established
biological disruptor of the lung microvascular barrier. HPMEC monolayer disruption was similarly evident
by immunofluorescence microscopy, demonstrating loss of junctional VE-cadherin and cortical actin,
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FIGURE 1 Plasma of coronavirus disease 2019 (COVID-19) patients induces endothelial barrier failure. a) Barrier integrity of pulmonary
microvascular endothelial cell monolayers assessed by electric cell impedance sensing (ECIS) in response to stimulation with 10% (v/v) plasma (at
t=0 h) of healthy controls (number of samples/donors: 17/14), and moderate (25/14) or severe (22/16) COVID-19 patients. In cases of multiple
samples from the same patient these were obtained at different time-points. Data are normalised to mean endothelial cell (EC) resistance in healthy
donors. b) Trans-endothelial electrical resistance (TEER) response of EC monolayers to stimulation with 10% (v/v) plasma (at t=0 h) of healthy
controls (7/7), and moderate (4/4), or severe (8/7) COVID-19 patients, with medium control and platelet activating factor as negative and positive
controls. c) Representative immunofluorescence images of EC monolayers treated for 6 h with 10% (v/v) plasma of either healthy donors or severe
COVID-19 patients stained for (left) VE-cadherin (cyan) or (centre) F-actin (green). Nuclei are shown in blue (DAPI). Gap area per cell (white in F-actin
images) was identified by an automated segmentation algorithm (selecting pixels with zero values in both the F-Actin and VE-cadherin channel)
using Fiji/MorpholibJ-Plugin, and was quantified for EC monolayers treated with plasma from healthy donors (7/7) or severe COVID-19 patients (7/7)
(right). d) Representative western blots and quantification of VE-cadherin and occludin protein levels (normalised to healthy donors) in human lung
samples from five donors treated for 24 h with plasma of three healthy donors or five severe COVID-19 patients. *: p⩽0.05.
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formation of actin stress fibres, and inter-endothelial gap formation in response to plasma from severe
COVID-19 patients as compared to healthy controls (figure 1c). Exposure of human lung tissue to severe
COVID-19 plasma caused loss of the junctional molecule occludin while changes in VE-cadherin protein
levels did not reach statistical significance (figure 1d). All plasma samples, as well as cell lysates and
supernatants from plasma-exposed HPMECs tested negative for SARS-CoV-2 RNA.
Here, we demonstrate that plasma from COVID-19 patients induces robust barrier failure of the lung
microvascular endothelium. This barrier-disruptive potential of plasma increased from moderate to severe
disease, a finding that is in line with proteomic analyses demonstrating changes in inflammatory plasma
biomarkers as a function of disease severity [4]. While this barrier-disruptive effect is per se likely not
unique to COVID-19 and may be equally evident in other critically ill patients, the recent identification of
a distinct biomarker signature in the plasma of COVID-19 patients, as compared to e.g. severe influenza
infection [4], suggests the involvement of specific mediators or pathways in COVID-19-related endothelial
barrier failure.
Treatment of healthy endothelial monolayers with plasma of COVID-19 patients was associated with
significant endothelial gap formation and loss of junctional VE-cadherin in endothelial monolayers. Loss
of junctional proteins was also evident in human lung tissue, although large scatters in expression levels
resulted in considerable overlap between healthy and COVID-19-plasma treated human lung tissue. In line
with the clinical course of patients following SARS-CoV-2 infection, these findings indicate substantial
biological variability of the host tissue both at baseline and in response to stimulation with COVID-19
plasma. Notably, these effects were not attributable to a direct action of SARS-CoV-2 on the endothelium,
as demonstrated by the absence of viral RNA. Our findings provide proof-of-principle for the concepts
that 1) endothelial injury and barrier failure are characteristic features of severe COVID-19, 2) are caused
by endogenous plasma factors, rather than direct injury by viral infection, and 3) may drive the
progression from mild disease to critical ARDS [2, 5]. Notably, endothelial activation may not be restricted
to the regulation of vascular permeability, but could also contribute to other clinical manifestations of
COVID-19 associated vasculopathies, such as microthrombosis and vascular inflammation.
The present work in conjunction with our recent proteome analyses in COVID-19 plasma [4] provides for
a versatile platform to screen for the relevance of individual plasma mediators of endothelial permeability
in high throughput mode. To this end, correlative changes in plasma mediators and barrier failure as a
function of disease severity may guide the identification of key signalling mechanisms. Of equal relevance,
this platform allows to screen for the prophylactic or therapeutic effectiveness of drugs with demonstrated
barrier-protective action [4]. Importantly, the unique time profile of COVID-19 with a slow progression
from symptom onset to mild, moderate, and ultimately severe disease provides a model scenario for the
application of barrier-stabilising adjunctive therapies. We therefore propose that pharmacological
stabilisation of the endothelial barrier should be considered as a third pillar for the treatment of
COVID-19 in addition to anti-virals and immunomodulators.
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